Lifordi Immunotherapeutics Advances Glucocorticoid ADC LFD-200 into Phase 1 Rheumatoid Arthritis Trial Following Promising Nonclinical Data
Lifordi Immunotherapeutics has initiated Phase 1 clinical trials for LFD-200, a novel antibody-drug conjugate that delivers glucocorticoids directly to immune cells, potentially overcoming the systemic toxicity limitations that have restricted steroid use in autoimmune diseases for decades.
Lifordi Immunotherapeutics has moved its lead antibody-drug conjugate candidate LFD-200 into Phase 1 clinical trials for rheumatoid arthritis following compelling nonclinical data presented at the American College of Rheumatology Convergence 2025 meeting. The company announced that initial data from healthy participants in the single ascending dose/multiple ascending dose study are expected by the end of 2025, marking a significant milestone in autoimmune treatment development.
The nonclinical data demonstrated that LFD-200 achieves sustained glucocorticoid exposure in immune cells of non-human primates for at least seven days following a single dose. The treatment suppressed proinflammatory cytokine expression without evidence of toxicity after 13 weekly, clinically relevant doses. Immunohistochemistry detected the glucocorticoid payload in immune tissues of lymph nodes and spleen seven days after administration, showing targeted delivery to the intended cellular compartments.
Dr. Matthew W. McClure, Chief Medical Officer of Lifordi, presented results showing LFD-200 dose-dependently reduces proinflammatory cytokines after ex vivo stimulation of whole blood and bone marrow. The treatment demonstrated reduced levels of TNFα and IL-1β after single doses at 5 mg/kg or 20 mg/kg. Crucially, the data revealed no cortisol suppression at clinically relevant doses, unlike traditional glucocorticoid treatments that often cause adrenal suppression.
After 13 weekly doses of LFD-200 at 25 mg/kg, researchers observed no reduction in bone formation markers or bone mineral density, addressing one of the most significant limitations of chronic steroid therapy. The poster detailing these findings, "LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates," is available for review at https://www.lifordi.com.
Dr. McClure emphasized the historical significance of this approach, stating that "the ability to harness the anti-inflammatory effects of glucocorticoids while limiting systemic toxicities has been the 'holy grail' of autoimmune treatment for 75 years." The company's VISTA-targeted delivery approach enables selective delivery to immune cells, potentially revolutionizing how autoimmune conditions are managed by maintaining therapeutic efficacy while minimizing the debilitating side effects that have limited steroid use.
Arthur Tzianabos, Ph.D., President and Chief Executive Officer, highlighted the rapid progression from laboratory to clinical studies, noting the program's advancement in just over two years. The company now aims to demonstrate whether the promising nonhuman primate data translates to human studies, first establishing safety and cytokine suppression in healthy participants before moving to proof-of-mechanism studies in rheumatoid arthritis patients.
This development represents a potential paradigm shift in autoimmune disease treatment, particularly for rheumatoid arthritis, where glucocorticoids remain highly effective but their clinical utility is constrained by dose-limiting toxicities. The targeted delivery approach could enable more sustained and effective treatment of inflammatory conditions while preserving patients' quality of life by avoiding the metabolic, bone, and adrenal complications associated with conventional steroid therapies.